drugset / Trial / NCT02015559

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus

NCT02015559 ↗

RandomizedParallel-groupOpen-labelSupportive care

Summary

This randomized phase II trial studies how well mucoadhesive oral wound rinse works in preventing and treating stomatitis in patients with estrogen receptor (ER)- or progesterone receptor (PR)-positive metastatic or locally recurrent breast cancer that cannot be removed by surgery receiving everolimus. Mucoadhesive oral wound rinse may help prevent symptoms of stomatitis, or mouth sores, in patients receiving everolimus.

Timeline

Start
2014-10-08
Primary completion
2018-11-30
Completion
2018-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject MuGard Unknown — Oral